Azitra doses first subject in Phase Ib Netherton syndrome treatment trial [Yahoo! Finance]
Azitra Inc (AZTR)
Company Research
Source: Yahoo! Finance
This trial plans to enrol approximately 12 adults who will receive the treatment twice daily for 14 days. The company previously screened the first subject in its Phase Ib trial of ATR-12 for treating Netherton syndrome. The primary goals are to assess the safety and tolerability of the topical ATR-12 treatment while secondary objectives will focus on evaluating efficacy signals, biomarkers, and skin pharmacokinetics of the LEKTI subunit. Exploratory objectives, such as pharmacodynamic parameters, biomarkers, anti-LEKTI response, and cytokine responses, will also be analysed. Azitra anticipates releasing interim safety data in early 2025, with full results expected in the latter half of the year. ATR-12 is Azitra leading candidate and a specially engineered strain of Staphylococcus epidermidis designed to deliver therapeutic levels of a LEKTI protein subunit to combat Netherton syndrome, a serious genetic skin condition. Azitra CEO Francisco Salva said: “Dosing the first
Show less
Read more
Impact Snapshot
Event Time:
AZTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZTR alerts
High impacting Azitra Inc news events
Weekly update
A roundup of the hottest topics
AZTR
News
- Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business UpdatesPR Newswire
- Azitra to Present at BIO-Europe 2024Business Wire
- Azitra to Participate in the 2024 Maxim Healthcare Virtual SummitBusiness Wire
- Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology CongressBusiness Wire
AZTR
Sec Filings
- 11/13/24 - Form 8-K
- 11/12/24 - Form 10-Q
- 11/6/24 - Form SC
- AZTR's page on the SEC website